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Introduction 
Patients with rheumatoid arthritis (RA) typically experience substantial loss of lean mass (LM), primarily 
muscle mass (MM), and increased fat mass (FM), especially trunk FM, in a process known as “rheumatoid 
cachexia” (RC) (1). Thought to be driven by inlammation, speciically pro-inlammatory cytokines such as 
tumor necrosis factor-α, RC is a major contributor to decreased strength and impaired physical function 
and exacerbated co-morbidity risk, which characterize RA (1-3). Unfortunately, despite usually achieving 
successful control of inlammation and disease activity, current treatment of RA does not reverse these 
adverse changes in body composition (3).
When RA is “active” (i.e., before starting drug treatment or during a disease lare in established RA), one-of 
administration of high-dose corticosteroid (CS), often by intramuscular (IM) injection, is recommended in 
clinical guidelines (e.g., American College of Rheumatology (ACR), European League against Rheumatism 
(EULAR), British Society for Rheumatology (BSR), and NICE Clinical Guidelines 79, 2009) owing to its eicacy 
in rapidly reducing inlammation and pain (4-8). While long-term high-dose CS treatment is known to have 
detrimental efects on body composition including loss of LM and an increase in FM, the efects on body 
composition of single high-dose CS treatment, including IM CS injection, are unclear (9). 
Our interest in the body composition efects of acute CS treatment was stimulated by the observation of 
a substantial loss of dual-energy X-ray absorptiometry (DXA)-assessed MM (-2.0 kg in appendicular lean 
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Abstract
Objective: Adverse changes in body composition, specifically decreased muscle mass (MM) and in-
creased fat mass, characterize rheumatoid arthritis (RA). These changes, termed rheumatoid cachexia 
(RC), are important contributors to the disability and elevated co-morbidity risk of RA. Recently, we 
observed substantial muscle loss (~2 kg) in a patient with RA following a single intramuscular (IM) cor-
ticosteroid (CS) injection to treat a disease flare. The aim of the current study is to determine whether 
this apparent iatrogenic effect of IM CS is typical, i.e., does this routine, recommended treatment 
contribute to RC?
Methods: Body composition was assessed by dual-energy X-ray absorptiometry (DXA) in eight pa-
tients with established RA who received a 120 mg IM methylprednisolone injection to treat a disease 
flare. DXA scans estimated appendicular lean mass (ALM; a surrogate measure of MM), total lean mass 
(LM), and total and regional adiposity at baseline (injection day) and 4 weeks and 6-9 months post-in-
jection. Statistical analysis was performed using one-way ANOVA.
Results: There was significant loss of ALM (-0.93 kg, p=0.001, 95% CI [-0.49, -1.36]) and a trend toward 
reduced LM (-1.10 kg, p=0.165, 95% CI [0.58, -2.79]) at 4 weeks relative to baseline. At 6-9 months 
despite control of inflammation and disease activity, these losses remained.
Conclusion: Substantial muscle loss occurred in patients with RA following IM CS injection to treat a 
disease flare. Thus, this recommended treatment appears to exacerbate RC, thereby potentially in-
creasing disability and co-morbidity risk. If this effect is confirmed by larger studies, the role of one-off 
high-dose CS in the treatment of RA should be reviewed.
Keywords: Rheumatoid arthritis, body composition, rheumatoid cachexia, corticosteroids, disease 
flare
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mass, ALM; i.e., ~7% of total ALM) in a patient 
with RA following a single CS injection given 
to treat a disease lare (10). A search of the lit-
erature revealed only one other case report of 
local muscle loss following CS injection (11). 
However, in this report, assessment of mus-
cle loss was only made by visual observation. 
Nonetheless, these two reported cases raise 
concerns that high-dose CS injection treat-
ment may be contributing to the reduced 
MM that we recently reported persists even 
in patients with aggressively and successfully, 
pharmacologically treated contemporary RA 
(3).
To our knowledge, this pilot study is the irst 
to investigate the efects on body composi-
tion of a single high-dose IM CS injection. We 
hypothesized that this routine, recommended 
treatment for high RA disease activity exacer-
bates muscle loss and thus could contribute to 
the impaired physical function seen in patients 
with RA.
Methods
Participants
Patients with established RA presenting 
with a disease flare and treated with an IM 
injection of CS were recruited from the rheu-
matology outpatient clinics of the Peter 
Maddison Rheumatology Centre, Gwynedd 
Hospital. For inclusion, participants had to: 
(a) fulfill the ACR/EULAR 2010 revised clas-
sification criteria for the diagnosis of RA, (b) 
have uncontrolled RA disease activity for 
which IM CS injection was deemed to be 
the appropriate treatment, (c) be aged ≥18 
years, (d) not be cognitively impaired, (e) be 
free of other cachectic diseases or condi-
tions, (f ) not be pregnant, and (g) not have 
any contraindication to high-dose IM CS in-
jection (e.g., uncontrolled diabetes mellitus, 
active infection, and previous hypersensitivi-
ty to CS injections). 
This pragmatic, uncontrolled, pre-post-inter-
vention pilot study was approved by the North 
Wales Research Ethics Committee - West (15/
WA/0013).
Clinical assessments and treatment
Active disease (i.e., lare) was determined by 
the attending consultant rheumatologist fol-
lowing clinical assessment. If considered ap-
propriate by the same rheumatologist, and 
patient consent was obtained, a standard CS 
injection, 120 mg of Depomedrone (methyl-
prednisolone acetate aqueous solution), was 
administered into the gluteal muscle. 
Patient’s disease activity (Disease Activity 
Score in 28 joints, DAS28-CRP) and systemic 
inlammation (C-reactive protein, CRP) were 
determined at baseline (immediately prior to 
injection) and during routine rheumatology 
follow-up clinics at approximately 4 weeks (27-
32 days) and 6-9 months post-injection. 
Body composition measures 
DXA scans were performed within 1 hour of 
the patient receiving the injection (baseline) 
and repeated at ~4 weeks and 6-9 months 
post-injection. Total and regional lean and 
fat masses, along with bone mineral content 
(BMC) and density (BMD), were estimated us-
ing a whole body fan beam DXA scanner (Ho-
logic, QDR Discovery 45615, software V12.4). 
ALM (the summed LM of the arms and legs) 
served as a surrogate measure of total body 
MM (3). The in-house coeicient of variation of 
1.4% of our scanner complies with the manu-
facturer’s guidelines (3).
Statistical analysis
The primary outcome measure was DXA-as-
sessed ALM, with secondary outcome mea-
sures of: disease activity (DAS28-CRP) and 
systemic inlammation (CRP) and other body 
composition variables: total LM, % ALM relative 
to body mass (BM) (ALM/BM %), total FM, trunk 
FM, % FM relative to BM (% body fat), % trunk 
FM relative to total FM (trunk FM %), BMC, and 
BMD.
Data analyses were performed by one-way 
ANOVAs (three time-points), with efect size 
(small=0.20-0.49, medium=0.50-0.79, and 
large ≥0.80) calculated for each variable. Data 
analyses were performed using the Statistical 
Package for the Social Sciences 22 (IBM Corp.; 
Armonk, NY, USA). Data are generally present-
ed as mean (±SD), with between-time difer-
ences presented as mean (±95% conidence 
intervals, 95% CI), and, where appropriate, 
range is also given. Signiicance was set at 
p<0.05. 
Results
Nine patients with RA who received an IM 
CS injection to treat a lare of disease were 
deemed eligible for the study and consent-
ed to participate. Assessments at baseline, 4 
weeks, and 6-9 months post-injection were 
performed on eight patients, as one partici-
pant withdrew from the study after baseline 
measurements owing to suspected meningitis. 
The mean interval between CS injection and 
baseline DXA scan was 0.7 h (~42 min; range: 
18-60 min). 
Table 1 shows the baseline demographic data 
for the eight patients who completed the 
study. All patients had established disease 
(mean duration ~11 years, range: 2.0-46.8 
years) and were on standard disease-modify-
ing anti-rheumatic drug therapy. None of these 
patients, either at the time of the CS injection 
or over the ensuing 6-9 months, were treated 
with either biologics or oral steroids. Patients 
reported no substantial changes to lifestyle 
(e.g., diet or exercise) or adverse health events, 
over the trial period. 
Signiicant reductions in DAS28-CRP (p=0.049, 
95% CI [-0.82, -2.30]) and CRP (p=0.023, 95% 
CI [-0.78, -28.95]) from baseline to 4 weeks in-
dicated that the patients were responsive to 
the anti-inlammatory efects of IM CS (Table 
2). This response is also relected in 5 out of 
8 patients experiencing clinically meaningful 
improvements in DAS28 (reduction >1.2) and 
CRP (reduction >10 mg/L) in the 4 weeks fol-
lowing CS injection (Table 2). Measures at 6-9 
months indicated continued maintenance of 
control of disease activity and inlammation 
(data not shown), which was consistent with 
no reports of lares during this period.
Mean body composition changes over the 
study duration are shown in Table 3. Four 
weeks following IM CS injection, an average of 
0.93 kg ALM (i.e., MM) was lost, whereas mean 
total LM was reduced by 1.10 kg. All eight pa-
tients lost ALM in the month following IM CS 
injection, with seven losing >0.50 kg (Table 2). 
Mean proportional ALM (ALM/BM %, i.e., rela-
tive MM) was signiicantly reduced at 4 weeks 
post-injection. Although all mean measures 
of adiposity increased over this period, i.e., to-
tal FM (+0.70 kg), trunk FM (+0.53 kg), % body 
fat (+0.89%), and trunk FM % (+1.01%), none 
of these changes were statistically signiicant. 
Although there were no signiicant changes 
in any of the body composition measures be-
tween the follow-up assessments at 4 weeks 
and 6-9 months (p values=0.32-0.54), during 
which time control of inlammation and dis-
ease activity was maintained, LM measures 
Table 1. Baseline demographics of patients 
with rheumatoid arthritis receiving 
intramuscular corticosteroid injection to treat 
a disease flare (n=8)
Age (years)  61.4 (±7.2)
Sex (n female) (%) 6 (75)
Disease duration (months) 130.5 (±158.8)
DAS28-CRP 4.51 (±0.97)
CRP (mg/L) 23.4 (±20.9)
Data presented as mean (±SD) 
DAS28: Disease Activity Score in 28 joints; CRP: C-reactive 
protein
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tended to decline further, whereas FM mea-
sures regressed back to baseline levels (Table 
3). Thus, 6-9 months after IM CS injection, the 
depletion in ALM observed at 4 weeks had 
not spontaneously reversed, and patients re-
mained signiicantly muscle reduced relative 
to their baseline levels.
No changes in BMD or BMC were detected at 
4 weeks or 6-9 months (data not shown; p val-
ues=0.620 or 0.664, respectively).
Discussion 
To our knowledge, the present study is the irst 
to objectively investigate the consequences 
of a single, high-dose administration of CS on 
body composition. Although only preliminary, 
results from eight patients, taken with a sim-
ilar observation from our case study, suggest 
that a single, high-dose IM CS injection used to 
treat active RA disease results in signiicant loss 
of ALM - a surrogate measure of skeletal MM 
(10). As this reduction in MM is likely to have 
adverse efects on physical function, these 
indings raise important concerns about the 
routine use of this treatment for patients with 
RA with active disease.
Patients presenting with uncontrolled RA 
are often treated by IM CS injection. Indeed, 
such injections are recommended by national 
guidelines for the management of active RA 
(e.g., ACR, EULAR, BSR, and NICE) because of 
their eicacy in rapidly attenuating inlamma-
tion and pain (4-8). Consistent with these rec-
ommendations and its regularly observed clin-
ical beneit, the CS injections administered in 
the present study ameliorated disease activity 
and inlammation, with mean DAS28 and CRP 
at 4 weeks being reduced, relative to baseline, 
by 35% and 64%, respectively. 
However, despite rapidly restoring control of 
inlammation and disease activity, there were 
mean losses of 0.93 kg and 1.46 kg in ALM (i.e., 
skeletal muscle), respectively, in the 4 weeks 
and 6-9 months following IM CS injection. 
This apparent iatrogenic loss of ALM accounts 
for approximately 37% of the discrepancy in 
proportional MM (i.e., ALM/BM %) between 
patients with RA and healthy age- and sex-
matched individuals we have previously re-
ported (3). Additionally, reduced MM, includ-
ing the magnitude of MM loss observed in the 
present study (~7% of total MM), is acknowl-
edged as a major contributor to the decreased 
strength and impaired physical function char-
Table 2. Individual changes in DAS28-CRP score, component DAS28-CRP scores, and ALM more than 4 weeks following a single, high-dose 
intramuscular corticosteroid injection to treat a rheumatoid arthritis disease flare
Patient DAS28-CRP CRP (mg/L) Swollen joints Tender joints Patient global score (VAS 0-100)
 Baseline 4 weeks Baseline 4 weeks Baseline 4 weeks Baseline 4 weeks Baseline 4 weeks ALM loss (kg)
1 4.42 1.66 17 5 4 0 8 0 20 4 1.02
2 3.42 1.54 4 4 0 0 4 0 54 0 0.56
3 4.93 2.90 67 15 1 0 4 1 75 27 1.92
4 5.20 4.42 5 5 11 3 6 8 75 53 0.86
5 3.69 2.28 20 5 7 2 0 0 64 20 1.42
6 3.28 2.86 40 19 4 1 0 0 30 39 0.62
7 5.96 3.40 20 5 3 4 15 3 89 19 0.31
8 5.18 4.52 14 10 9 11 11 6 39 28 0.72
Mean (SD)  4.51 (0.97) 2.95 (1.13) 23.4 (20.9) 8.5 (5.7) 4.8 (3.8) 2.6 (3.7) 6.0 (5.2) 2.3 (3.2) 55.8 (24.3) 23.8 (17.4) 0.93 (0.52)
DAS28: Disease Activity Score in 28 joints; CRP: C-reactive protein; VAS: Visual Analog Scale; ALM: appendicular lean mass; SD: standard deviation
Table 3. Body composition changes more than 4 weeks and 6-9 months following a single, high-dose intramuscular corticosteroid injection to 
treat a rheumatoid arthritis disease flare
DXA   Post-CS Absolute difference  Effect Post-CS Absolute difference  Effect 
measures Baseline (4 weeks) [95% CI] p size (6-9 months) [95% CI] p size
ALM (kg) 19.86 (±4.71) 18.93 (±4.57) -0.93 [-0.49, -1.36] 0.001* 0.54 18.40 (±4.32) -1.46 [-0.11, -3.61] <0.001* 0.67
ALM/BM % 25.7 (±2.6) 24.8 (±3.0) -0.91 [-0.42, -1.40] 0.003* 0.33 24.4 (±3.1) -1.3 [-0.62, -3.13] 0.001* 0.44
Total LM (kg) 48.02 (±5.32) 46.91 (±5.10) -1.11 [-0.58, -2.78] 0.165 0.21 46.50 (±5.20) -1.52 [-0.74, -4.56] 0.105 0.31
Total FM (kg) 31.81 (±6.27) 32.51 (±6.29) 0.70 [-0.99, 2.39] 0.362 0.11 31.90 (±6.49) 0.09 [-5.29, 6.56] 0.612 0.10
Body fat %  35.1 (±9.9) 36.0 (±11.0) 0.89 [-0.66, 2.43] 0.216 0.09 35.2 (±11.0) 0.09 [-1.46, 3.59] 0.786 0.07 
(total FM/BM %)
Trunk FM (kg) 14.76 (±4.59) 15.29 (±5.12) 0.53 [-0.66, 1.71] 0.327 0.12 14.91 (±5.12) 0.15 [-2.50, 4.37] 0.537 0.10
Trunk FM %  47.5 (±9.7) 48.5 (±11.0) 1.01 [-0.87, 2.89] 0.243 0.10 48.3 (±11.0) 0.83 [-0.83, 5.70] 0.366 0.08 
(trunk FM/total FM %)
Data presented as mean (±SD), unless stated otherwise. DXA: dual X-ray absorptiometry; CS: corticosteroid; CI: confidence interval; ALM: appendicular lean mass; BM: body mass; LM: lean mass; FM: 
fat mass; *p<0.05; effect size: small:0.20-0.49, medium:0.50-0.79, and large ≥0.80; p values and effect size vs baseline
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acteristic of RA (1-3). Further, loss of MM (and 
therefore loss of “expendable” protein) impairs 
the immune system’s ability to adequately re-
spond to infection and trauma (2). It is import-
ant to note that despite sustained low disease 
activity, the muscle lost at 4 weeks was not 
spontaneously restored by the 6-9 months 
post-injection follow-up assessment. This ind-
ing is not unexpected, as without some form 
of anabolic stimuli the body does not sponta-
neously recover lost MM; and in speciic regard 
to patients with RA, this remains the case even 
when disease remission is achieved (3). This 
further emphasizes the importance for ad-
junct interventions designed to increase MM 
in RA. Of the potential anabolic interventions 
trialed, progressive resistance training is clearly 
the most beneicial intervention for improving 
both MM and physical functioning in patients 
with RA (12).
With regard to the muscle loss we observed, 
an obvious question is whether this was a 
consequence of the inlammation associat-
ed with the disease lare. In response to this, 
we consider that systemic inlammation was 
unlikely to be a major contributor to the ALM 
loss seen in the present study because of i) 
the rapidity of the anti-inlammatory efects 
of high-dose CS, ii) the meaningful muscle 
loss (>0.5 kg ALM) observed 4 weeks follow-
ing IM CS injection experienced by subjects 
(#2,4; Table 2) who did not have systemic in-
lammation according to blood CRP level at 
baseline, and iii) the lack of association (deter-
mined by linear regression) between ALM loss 
and either DAS28 or CRP at baseline (R2=0.009, 
p=0.822 or R2=0.063, p=0.549, respectively). 
Additionally, our indings of reduced MM 
following IM CS injection are consistent with 
the established efect on skeletal muscle of 
chronic high-dose CS treatment. While the ex-
act mechanism underlying glucocorticoid-in-
duced reduction in MM is unclear, augment-
ed muscle protein breakdown via stimulation 
of the catabolic ubiquitin-proteasome system 
brought about by increased expression of 
atrogenes (genes, such as FOXO, Atrogin-1, 
and MuRF-1, involved in muscle atrophy) 
and attenuated muscle protein synthesis via 
inhibition of anabolic pathways (e.g., mTOR/
S6 kinase 1, PI3K/Akt, and insulin-like growth 
factor-I) have been observed (for a review see) 
(13). 
Given that IM CS injection is often adminis-
tered to patients following diagnosis of RA and 
again when patients with established RA ex-
perience disease lares, it is not unusual for pa-
tients with RA to receive this form of treatment 
several times during the course of their disease 
(three occasions (range: 2-4) on average for the 
patients in the current study). Thus, this recom-
mended treatment could be a signiicant con-
tributor to RC and, in particular, the deiciency 
in MM observed in patients with RA. 
Chronic CS use has also been implicated in the 
redistribution of fat to the truncal area (14). Al-
though we saw no mean change in patients’ 
total FM, we did observe a non-signiicant 3.5% 
increase in trunk FM % at 4 weeks following 
acute administration of high-dose CS. As such, 
this is another aspect of body composition that 
warrants attention in a future large study evalu-
ating the efects of one-of high-dose CS treat-
ment. A shift in adiposity, if conirmed, would 
be worrying as trunk obesity, a feature of RA 
body composition, exacerbates cardiovascu-
lar disease risk (2, 3, 15). However, it should be 
noted that, in contrast to the changes in LM 
measures observed at 4 weeks, the apparent 
changes observed in FM measures at 4 weeks 
had all been resolved by 6-9 months. Although 
chronic and acute IM CS uses are known to in-
crease osteoporosis risk, we saw no changes in 
bone measures (BMD or BMC) at either time-
point (14, 16).
We acknowledge several limitations of our 
pilot study. First, the low n of our sample, 
and the inclusion of only patients with estab-
lished RA who were experiencing a disease 
lare. These make it di cult to generalize the 
efect of IM CS injection we observed in all 
patients with RA, notably patients recently 
diagnosed with RA. Accordingly, to conirm 
the generality of these body composition ef-
fects of IM CS treatment for active RA, we have 
recently commenced a large, clinic-based 
study (n~100) which will mostly include treat-
ment-naïve patients recently diagnosed with 
RA. However, in defense of the results from 
our pilot study, we feel that the very consis-
tent pattern of muscle loss (Table 2, plus our 
case study) justiies concerns that IM CS injec-
tion may cause clinically meaningful muscle 
loss in patients with RA (10). The lack of ran-
dom and controlled treatment assignment 
may also be considered a weakness of our 
study design. However, this was unavoidable 
in a pragmatic, observational study of routine 
clinical practice. Additionally, denying treat-
ment to patients with highly active RA would 
be unethical. 
The results from this pilot study indicate that a 
single IM injection of high-dose CS, a recom-
mended and standard treatment for uncon-
trolled disease activity in RA, causes substantial 
and clinically relevant loss of MM. Since short-
term, high-dose treatment with CS, including 
administration by IM injection, is undoubtedly 
the most cost-efective treatment current-
ly available to combat high levels of inlam-
mation in RA, we are not suggesting that this 
treatment is discontinued, as unresolved in-
lammation will also result in muscle loss (1). 
However, we are advocating that ways of at-
tenuating this apparent iatrogenic efect of IM 
CS injection should be investigated, as should 
potential alternative treatments for rapidly re-
solving the inlammation and pain of uncon-
trolled RA. 
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